Syncona
Limited
Issue of shares pursuant to
incentive scheme and PDMR dealings
19 July 2024
Syncona Ltd (the "Company"), a
leading life science investor focused on creating, building and
scaling global leaders in life science, today announces that a
total of 407,966 new ordinary shares (representing approximately
0.06% of the Company's existing issued ordinary shares, excluding
shares held in treasury) will be issued in satisfaction
of realisations under the Company's long term incentive
scheme. The new ordinary shares, when issued, will rank pari
passu with the existing issued ordinary shares of the
Company. In accordance with the rules of the incentive scheme,
the number of ordinary shares to be issued has been calculated
using the closing mid-market price on 17 July, 2024,
£1.25.
In accordance with the rules of the
incentive scheme, ordinary shares delivered on realisation may not
be sold or transferred by the recipient for a period of one year
following the realisation date.
The issue of shares includes the
following shares to be issued to senior members of the Syncona
Investment Management Limited (SIML) leadership team:
Name
|
SIML Title
|
No.
of shares to be issued
|
Chris Hollowood
|
Chief Executive Officer
|
134,082
|
Application will be made to the
Financial Conduct Authority for the shares to be admitted to the
Official List, and to the London Stock Exchange for the shares to
be admitted to trading and it is expected that dealings will
commence in the new ordinary shares on 24 July 2024.
Notification of transactions by
Persons Discharging Managerial Responsibilities ("PDMRs") are set
out below.
[ENDS]
Enquiries
Syncona Ltd
Natalie Garland-Collins / Fergus
Witt
Tel: +44 (0) 20 3981 7940
FTI Consulting
Ben Atwell / Tim Stamper
Tel: +44 (0) 20 3727
1000
About Syncona
Syncona's purpose is to invest to
extend and enhance human life. We do this by creating, building and
scaling companies to deliver transformational treatments to
patients in areas of high unmet need.
We aim to build and maintain a
diversified portfolio of 20-25 globally leading life science
businesses, across development stage, modality and therapeutic
area, for the benefit of all our stakeholders. We focus on
developing treatments that deliver patient impact by working in
close partnership with world-class academic founders and
experienced management teams. Our balance sheet underpins our
strategy, enabling us to take a long-term view as we look to
improve the lives of patients with no or poor treatment options,
build sustainable life science companies and deliver strong
risk-adjusted returns to shareholders.
Syncona Limited seeks to
achieve returns over the long term. Investors should seek to ensure
they understand the risks and opportunities of an investment
in Syncona Limited, including the information in our published
documentation, before investing.
Copies of this press release and
other corporate information can be found on the company website
at: www.synconaltd.com
1.
|
Details of PDMR / person closely
associated with them ("PCA")
|
a)
|
Name
|
Chris Hollowood
|
2.
|
Reason for the
notification
|
a)
|
Position / status
|
Chair and Chief Executive Officer,
SIML
|
b)
|
Initial notification /
amendment
|
Initial Notification
|
3.
|
Details of the issuer, emission
allowance market participant, auction platform, auctioneer or
auction monitor
|
a)
|
Name
|
Syncona Limited
|
b)
|
LEI
|
213800X8MBI5VQITLW60
|
4.
|
Details of the transaction(s):
section to be repeated for (i) each type of instrument; (ii) each
type of transaction; (iii) each date; and (iv) each place where
transactions have been conducted
|
a)
|
Description of the financial
instrument
|
Ordinary shares
GG00B8P59C08
|
b)
|
Nature of the transaction
|
Issue of shares pursuant to the
Syncona long term incentive scheme
|
c)
|
Price(s) and volume(s)
|
Price(s)
£1.25
|
Volume(s)
134,082
|
|
|
|
d)
|
Aggregated information
Aggregated volume
Price
|
N/A
|
e)
|
Date of the transaction
|
18 July 2024
|
)
|
Place of the transaction
|
Outside a trading venue
|
g)
|
Currency
|
GBP - British Pound
|